THERAVANCE BIOPHARMA INC (TBPH) Fundamental Analysis & Valuation

NASDAQ:TBPH • KYG8807B1068

13.57 USD
-0.01 (-0.07%)
At close: Mar 6, 2026
13.57 USD
0 (0%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TBPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to TBPH. TBPH was compared to 193 industry peers in the Pharmaceuticals industry. While TBPH seems to be doing ok healthwise, there are quite some concerns on its profitability. TBPH has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

3

1. TBPH Profitability Analysis

1.1 Basic Checks

  • TBPH had negative earnings in the past year.
  • In the past year TBPH had a positive cash flow from operations.
  • TBPH had negative earnings in 4 of the past 5 years.
  • TBPH had a negative operating cash flow in each of the past 5 years.
TBPH Yearly Net Income VS EBIT VS OCF VS FCFTBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

  • TBPH has a Return On Assets of 7.06%. This is amongst the best in the industry. TBPH outperforms 88.60% of its industry peers.
  • With an excellent Return On Equity value of 12.61%, TBPH belongs to the best of the industry, outperforming 87.05% of the companies in the same industry.
Industry RankSector Rank
ROA 7.06%
ROE 12.61%
ROIC N/A
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBPH Yearly ROA, ROE, ROICTBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • TBPH's Profit Margin of 36.53% is amongst the best of the industry. TBPH outperforms 96.37% of its industry peers.
  • TBPH does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 36.53%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBPH Yearly Profit, Operating, Gross MarginsTBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. TBPH Health Analysis

2.1 Basic Checks

  • TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TBPH has more shares outstanding
  • Compared to 5 years ago, TBPH has less shares outstanding
  • TBPH has a worse debt/assets ratio than last year.
TBPH Yearly Shares OutstandingTBPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TBPH Yearly Total Debt VS Total AssetsTBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • TBPH has an Altman-Z score of 0.01. This is a bad value and indicates that TBPH is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 0.01, TBPH perfoms like the industry average, outperforming 51.30% of the companies in the same industry.
  • TBPH has a debt to FCF ratio of 0.13. This is a very positive value and a sign of high solvency as it would only need 0.13 years to pay back of all of its debts.
  • TBPH has a better Debt to FCF ratio (0.13) than 97.41% of its industry peers.
  • A Debt/Equity ratio of 0.14 indicates that TBPH is not too dependend on debt financing.
  • The Debt to Equity ratio of TBPH (0.14) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 0.13
Altman-Z 0.01
ROIC/WACCN/A
WACC9.29%
TBPH Yearly LT Debt VS Equity VS FCFTBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • TBPH has a Current Ratio of 9.48. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
  • TBPH's Current ratio of 9.48 is fine compared to the rest of the industry. TBPH outperforms 78.76% of its industry peers.
  • A Quick Ratio of 9.48 indicates that TBPH has no problem at all paying its short term obligations.
  • The Quick ratio of TBPH (9.48) is better than 78.76% of its industry peers.
Industry RankSector Rank
Current Ratio 9.48
Quick Ratio 9.48
TBPH Yearly Current Assets VS Current LiabilitesTBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TBPH Growth Analysis

3.1 Past

  • The earnings per share for TBPH have decreased strongly by -10.53% in the last year.
  • The Revenue has grown by 27.12% in the past year. This is a very strong growth!
  • Measured over the past years, TBPH shows a decrease in Revenue. The Revenue has been decreasing by -2.59% on average per year.
EPS 1Y (TTM)-10.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%126.92%
Revenue 1Y (TTM)27.12%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%18.51%

3.2 Future

  • TBPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.57% yearly.
  • The Revenue is expected to grow by 26.23% on average over the next years. This is a very strong growth
EPS Next Y277.49%
EPS Next 2Y69.83%
EPS Next 3Y24.96%
EPS Next 5Y19.57%
Revenue Next Year71.99%
Revenue Next 2Y26.75%
Revenue Next 3Y23.76%
Revenue Next 5Y26.23%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

5

4. TBPH Valuation Analysis

4.1 Price/Earnings Ratio

  • TBPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • TBPH is valuated correctly with a Price/Forward Earnings ratio of 14.08.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TBPH indicates a rather cheap valuation: TBPH is cheaper than 83.42% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.57. TBPH is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 14.08
TBPH Price Earnings VS Forward Price EarningsTBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, TBPH is valued cheaply inside the industry as 98.45% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2.82
EV/EBITDA N/A
TBPH Per share dataTBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

  • TBPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as TBPH's earnings are expected to grow with 24.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.83%
EPS Next 3Y24.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TBPH Dividend Analysis

5.1 Amount

  • No dividends for TBPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TBPH Fundamentals: All Metrics, Ratios and Statistics

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (3/6/2026, 8:00:02 PM)

After market: 13.57 0 (0%)

13.57

-0.01 (-0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners97.32%
Inst Owner Change2.36%
Ins Owners4.25%
Ins Owner Change-5.89%
Market Cap687.59M
Revenue(TTM)80.33M
Net Income(TTM)29.34M
Analysts81.54
Price Target27.25 (100.81%)
Short Float %9.29%
Short Ratio9.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.59%
Min EPS beat(2)-178.66%
Max EPS beat(2)153.48%
EPS beat(4)1
Avg EPS beat(4)-21.5%
Min EPS beat(4)-178.66%
Max EPS beat(4)153.48%
EPS beat(8)2
Avg EPS beat(8)-16.75%
EPS beat(12)4
Avg EPS beat(12)-14.07%
EPS beat(16)4
Avg EPS beat(16)-30.83%
Revenue beat(2)0
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-1.81%
Max Revenue beat(2)-1.36%
Revenue beat(4)1
Avg Revenue beat(4)0.44%
Min Revenue beat(4)-2.67%
Max Revenue beat(4)7.58%
Revenue beat(8)3
Avg Revenue beat(8)-0.1%
Revenue beat(12)4
Avg Revenue beat(12)-3.78%
Revenue beat(16)6
Avg Revenue beat(16)-3.51%
PT rev (1m)0%
PT rev (3m)28.23%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)-1.24%
EPS NY rev (1m)0.08%
EPS NY rev (3m)105.42%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)10.2%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-4.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.08
P/S 8.56
P/FCF 2.82
P/OCF 2.82
P/B 2.96
P/tB 2.96
EV/EBITDA N/A
EPS(TTM)-1.05
EYN/A
EPS(NY)0.96
Fwd EY7.1%
FCF(TTM)4.81
FCFY35.41%
OCF(TTM)4.81
OCFY35.44%
SpS1.59
BVpS4.59
TBVpS4.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 7.06%
ROE 12.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 36.53%
GM N/A
FCFM 303.11%
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 0.13
Debt/EBITDA N/A
Cap/Depr -13.08%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 829.74%
Current Ratio 9.48
Quick Ratio 9.48
Altman-Z 0.01
F-Score9
WACC9.29%
ROIC/WACCN/A
Cap/Depr(3y)53.03%
Cap/Depr(5y)62.83%
Cap/Sales(3y)1.99%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%126.92%
EPS Next Y277.49%
EPS Next 2Y69.83%
EPS Next 3Y24.96%
EPS Next 5Y19.57%
Revenue 1Y (TTM)27.12%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%18.51%
Revenue Next Year71.99%
Revenue Next 2Y26.75%
Revenue Next 3Y23.76%
Revenue Next 5Y26.23%
EBIT growth 1Y16.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y259.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y262.26%
OCF growth 3YN/A
OCF growth 5YN/A

THERAVANCE BIOPHARMA INC / TBPH FAQ

What is the fundamental rating for TBPH stock?

ChartMill assigns a fundamental rating of 4 / 10 to TBPH.


What is the valuation status for TBPH stock?

ChartMill assigns a valuation rating of 5 / 10 to THERAVANCE BIOPHARMA INC (TBPH). This can be considered as Fairly Valued.


How profitable is THERAVANCE BIOPHARMA INC (TBPH) stock?

THERAVANCE BIOPHARMA INC (TBPH) has a profitability rating of 3 / 10.


Can you provide the financial health for TBPH stock?

The financial health rating of THERAVANCE BIOPHARMA INC (TBPH) is 6 / 10.


What is the earnings growth outlook for THERAVANCE BIOPHARMA INC?

The Earnings per Share (EPS) of THERAVANCE BIOPHARMA INC (TBPH) is expected to grow by 277.49% in the next year.